Inactive Instrument

Company Veru Inc Nasdaq

US3144621022

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sales per Business

USD in Million	2022	Weight	2023	Weight	Delta
Female Condom/FC2 Internal Condom 99.9 %	39	100.0 %	16	99.9 %	-58.62%
Other 0.1 %	0	0.0 %	0	0.1 %	+438.84%

Sales per region

USD in Million	2022	Weight	2023	Weight	Delta
United States 51.4 %	31	79.9 %	8	51.4 %	-73.37%
Other 36.7 %	8	20.1 %	6	36.7 %	-24.47%
South Africa 11.9 %	-	-	2	11.9 %	-

Managers

Managers	Title	Age	Since
Harry Fisch FOU	Founder	66	01/71/01
Mitchell Steiner CEO	Chief Executive Officer	63	31/16/31
Michele Greco DFI	Director of Finance/CFO	65	01/13/01
Domingo Rodriguez CTO	Chief Tech/Sci/R&D Officer	62	01/18/01
K. Barnette CTO	Chief Tech/Sci/R&D Officer	56	01/18/01
Samuel Fisch IRC	Investor Relations Contact	-	-
Sergi Trilla PRN	Corporate Officer/Principal	-	01/22/01
Denise van Dijk PRN	Corporate Officer/Principal	-	-
Michael Purvis LAW	General Counsel	-	01/21/01
Philip Greenberg PRN	Corporate Officer/Principal	-	-

Members of the board

Members of the board	Title	Age	Since
Mitchell Steiner CEO	Chief Executive Officer	63	31/16/31
Xiao Qin Lu BRD	Director/Board Member	49	31/16/31
Michael Rankowitz BRD	Director/Board Member	66	01/18/01
Harry Fisch FOU	Founder	66	01/71/01
Mario Eisenberger BRD	Director/Board Member	75	31/16/31
Grace Hyun BRD	Director/Board Member	53	01/20/01

Share class

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	148,567,624	120,377,659 ( 81.03 %)	2,183,704 ( 1.470 %)	81.03 %

Shareholders

Name	Equities	%	Valuation
Adage Capital Partners GP LLC 7.530 %	11,022,222	7.530 %	11 M $
Harry Fisch 5.475 %	8,013,832	5.475 %	8 M $
Millennium Management LLC 5.192 %	7,600,502	5.192 %	8 M $
Mitchell Steiner 4.841 %	7,086,709	4.841 %	7 M $
Perceptive Advisors LLC 3.815 %	5,584,699	3.815 %	6 M $
Phillip Frost 3.484 %	5,100,253	3.484 %	5 M $
Vanguard Global Advisers LLC 3.223 %	4,717,908	3.223 %	5 M $
Rosalind Advisors, Inc. 3.074 %	4,500,000	3.074 %	5 M $
Octagon Capital Advisors LP 2.596 %	3,800,000	2.596 %	4 M $
Morgan Stanley Investment Management, Inc. 1.866 %	2,731,799	1.866 %	3 M $